Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Pediatric Eosinophilic Esophagitis: Traditional and Novel Therapies

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review presents and summarizes the existing studies on the treatment goals and options for pediatric eosinophilic esophagitis utilizing rigorous peer-reviewed literature.

Recent Findings

In addition to traditional treatments, emerging biologic therapies continue to evolve the approach to treating pediatric eosinophilic esophagitis. Well defined treatment goals will aid the continued development of new therapies. Further, innovative assessment tools have changed how the clinician is able to assess the effectiveness of therapies with a trend toward less invasive options.

Summary

The management of pediatric eosinophilic esophagitis continues to evolve with the advent of both novel treatment options and assessment tools. Treatment choices, with benefits and risks involved, should be presented to families upon diagnosis and tailored towards the individual patient and likelihood of adherence and success. Biologic therapy for EoE presents an exciting option for both first line therapy and escalation for those with severe or unresponsive disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data Availability

No datasets were generated or analyzed during the current study.

References

  1. Dellon ES, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Gastroenterology. 2018;155(4):1022–1033e10. The most recent consensus guidelines regarding the diagnosis of eosinohpilic esophagitis. These guidelines removed the prior diagnostic requirement that patients must first fail a trial of proton pump inhibitor.

    Article  PubMed  Google Scholar 

  2. Arias A, et al. Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2016;43(1):3–15.

    Article  CAS  PubMed  Google Scholar 

  3. Allin KH, et al. Eosinophilic oesophagitis in Denmark: Population-based incidence and prevalence in a nationwide study from 2008 to 2018. United Eur Gastroenterol J. 2022;10(7):640–50.

    Article  Google Scholar 

  4. Dellon ES, Hirano I. Epidemiology and natural history of Eosinophilic Esophagitis. Gastroenterology. 2018;154(2):319–332e3.

    Article  PubMed  Google Scholar 

  5. Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2014;113(6):624–9.

    Article  PubMed  Google Scholar 

  6. Warners MJ, et al. The natural course of eosinophilic esophagitis and long-term consequences of undiagnosed disease in a large cohort. Am J Gastroenterol. 2018;113(6):836–44.

    Article  PubMed  Google Scholar 

  7. Pentiuk S, et al. Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2009;48(2):152–60.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Safroneeva E, et al. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. Gastroenterology. 2016;150(3):581–590e4.

    Article  PubMed  Google Scholar 

  9. Hirano I, Furuta GT. Approaches and Challenges to Management of Pediatric and adult patients with eosinophilic esophagitis. Gastroenterology. 2020;158(4):840–51.

    Article  CAS  PubMed  Google Scholar 

  10. Ma C, et al. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol. 2022;149(2):659–70. Established the first core outcome set for both adult and pediatric eosinophilic esophagitis treatment. This will enable a more uniform approach to research and clinical trials.

    Article  PubMed  Google Scholar 

  11. Eke R, et al. Systematic review of histological remission criteria in eosinophilic esophagitis. JGH Open. 2018;2(4):158–65.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Collins MH, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017;30(3):1–8. Developed and validated the first histologic scoring system for eosinophilic esophagitis which evaluates histopathologic findings beyond peak eosinophil count. This may prove to be even more relevant in light of a shifting understanding of disease pathology that eosinophils may not drive inflammation and fibrosis.

    CAS  PubMed  Google Scholar 

  13. Ma C, et al. Responsiveness of a histologic Scoring System compared with peak Eosinophil Count in Eosinophilic Esophagitis. Am J Gastroenterol. 2022;117(2):264–71.

    Article  PubMed  Google Scholar 

  14. Kliewer KL, et al. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol; 2023.

  15. Wechsler JB, et al. Eosinophilic esophagitis reference score accurately identifies Disease Activity and Treatment Effects in Children. Clin Gastroenterol Hepatol. 2018;16(7):1056–63.

    Article  PubMed  Google Scholar 

  16. Ahuja N, et al. Applying the eosinophilic Esophagitis Endoscopic reference scores (EREFS) to different aged children. J Pediatr Gastroenterol Nutr. 2020;71(3):328–32.

    Article  PubMed  Google Scholar 

  17. Dellon ES, et al. Accuracy of the eosinophilic Esophagitis Endoscopic reference score in diagnosis and determining response to treatment. Clin Gastroenterol Hepatol. 2016;14(1):31–9.

    Article  PubMed  Google Scholar 

  18. Hudgens S, et al. Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension. J Patient Rep Outcomes. 2017;1(1):3.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Franciosi JP, et al. Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. BMC Gastroenterol. 2011;11:126.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Aceves SS, et al. Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. J Allergy Clin Immunol. 2018;142(1):130–138e1.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Warners MJ, et al. Systematic review: Disease Activity Indices in Eosinophilic Esophagitis. Am J Gastroenterol. 2017;112(11):1658–69.

    Article  PubMed  Google Scholar 

  22. Lynch MK, et al. Disease-Related predictors of Health-Related Quality of Life in Youth with Eosinophilic Esophagitis. J Pediatr Psychol. 2018;43(4):464–71.

    Article  PubMed  Google Scholar 

  23. Dellon ES, et al. A clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and future directions. Gastroenterology. 2022;163(1):59–76.

    Article  PubMed  Google Scholar 

  24. Kelly KJ et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula Gastroenterology, 1995. 109(5): p. 1503-12. ● A key study which first demonstrated food allergen elimination led to improvement in eosinophilic esophagitis histology.

  25. Arias A, et al. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology. 2014;146(7):1639–48.

    Article  PubMed  Google Scholar 

  26. Philpott H, et al. Allergy tests do not predict food triggers in adult patients with eosinophilic oesophagitis. A comprehensive prospective study using five modalities. Aliment Pharmacol Ther. 2016;44(3):223–33.

    Article  CAS  PubMed  Google Scholar 

  27. Rank MA, et al. Technical Review on the management of eosinophilic esophagitis: a Report from the AGA Institute and the Joint Task Force on Allergy-Immunology practice parameters. Gastroenterology. 2020;158(6):1789–1810e15.

    Article  CAS  PubMed  Google Scholar 

  28. Eckmann JD, et al. Efficacy of Atopy Patch Testing in Directed Dietary Therapy of Eosinophilic Esophagitis: a pilot study. Dig Dis Sci. 2018;63(3):694–702.

    Article  PubMed  Google Scholar 

  29. Kagalwalla AF, et al. Efficacy of a 4-Food elimination Diet for Children with Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2017;15(11):1698–1707e7.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Molina-Infante J, et al. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: the 2-4-6 study. J Allergy Clin Immunol. 2018;141(4):1365–72. Changed the practice of diet therapy to a step-up approach which offers patients a more limited number of eliminations at initiation and only expanding eliminations if necessary to achieve remission. This approach was demonstrated to require fewer dietary restrictions and endoscopies, shortening the time needed to identify food allergent triggers.

    Article  PubMed  Google Scholar 

  31. Gonsalves N, Schwartz DB, Yang S, Zalewski GY, Amsden A, Mughal K, Manuel-Rubio S, Melin-Aldana M, Wershil H, Hirano BK, Kagalwalla I. Prospective trial of four food elimination diet demonstrates comparable effectiveness in the treatment of adult and pediatric eosinophilic esophagitis. Gastroenterology. 2013;144:S154.

    Article  Google Scholar 

  32. Mayerhofer C, et al. Efficacy of Elimination Diets in Eosinophilic Esophagitis: a systematic review and Meta-analysis. Clin Gastroenterol Hepatol; 2023.

  33. Kruszewski PG, et al. Prospective, comparative effectiveness trial of cow’s milk elimination and swallowed fluticasone for pediatric eosinophilic esophagitis. Dis Esophagus. 2016;29(4):377–84.

    Article  CAS  PubMed  Google Scholar 

  34. Wechsler JB, Ross SS, Makhija J, Shaykin MM, Amsden R, Johnson K, Sulkowski K, Wershil M, Melin-Aldana BK, Kagalwalla H. Cow’s milk elimination for treatment of eosinophilic esophagitis: a prospective Pediatric Study. Gastroenterology. 2017;152(5):S855.

    Article  Google Scholar 

  35. Kliewer K, Atkins AS, Bonis D, Chehade PA, Collins M, Dellon MH, Fei ES, Gupta L, Kagalwalla SK, Mir AF, Mukkada S, Pesek V, Spergel R, Yang J, Rothenberg G. 817 – efficacy of 1-Food and 4-Food elimination diets for Pediatric Eosinophilic Esophagitis in a randomized multi-site study. Gastroenterology. 2019;156(6):S–172.

    Article  Google Scholar 

  36. Philpott H, Dellon E. Histologic improvement after 6 weeks of dietary elimination for eosinophilic esophagitis may be insufficient to determine efficacy. Asia Pac Allergy. 2018;8(2):e20.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Chang JW, et al. Development of a practical guide to Implement and Monitor Diet Therapy for Eosinophilic Esophagitis. Clin Gastroenterol Hepatol; 2023.

  38. Groetch M, et al. Dietary therapy and Nutrition Management of Eosinophilic Esophagitis: a Work Group Report of the American Academy of Allergy, Asthma, and Immunology. J Allergy Clin Immunol Pract. 2017;5(2):312–324e29.

    Article  CAS  PubMed  Google Scholar 

  39. Gupta SK, Vitanza JM, Collins MH. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015;13(1):66–76. e3.

    Article  CAS  PubMed  Google Scholar 

  40. Murali AR, et al. Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo-controlled randomized clinical trials. J Gastroenterol Hepatol. 2016;31(6):1111–9.

    Article  CAS  PubMed  Google Scholar 

  41. Rawla P, et al. Efficacy and safety of Budesonide in the treatment of eosinophilic esophagitis: updated systematic review and Meta-analysis of Randomized and Non-Randomized Studies. Drugs R D. 2018;18(4):259–69.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Dellon ES, et al. Safety and efficacy of budesonide oral suspension maintenance therapy in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2019;17(4):666–673e8.

    Article  CAS  PubMed  Google Scholar 

  43. Dellon ES, et al. Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis. Gastroenterology. 2017;152(4):776–786e5.

    Article  CAS  PubMed  Google Scholar 

  44. Hirano I, et al. Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial. Clin Gastroenterol Hepatol. 2022;20(3):525–534e10.

    Article  CAS  PubMed  Google Scholar 

  45. Lucendo AJ, et al. Efficacy of Budesonide Orodispersible Tablets as induction therapy for eosinophilic esophagitis in a Randomized Placebo-Controlled Trial. Gastroenterology. 2019;157(1):74–86e15.

    Article  CAS  PubMed  Google Scholar 

  46. Butz BK et al. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology, 2014. 147(2): p. 324 – 33 e5.

  47. Ketchem CJ et al. Treatment with compounded fluticasone suspension improves the clinicndoscopic, and histologic features of eosinophilic esophagitis. Dis Esophagus, 2021. 34(7).

  48. Andreae DA, et al. Swallowed Fluticasone Propionate is an effective long-term maintenance therapy for children with eosinophilic esophagitis. Am J Gastroenterol. 2016;111(8):1187–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Dellon ES, et al. Efficacy of Budesonide vs Fluticasone for initial treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial. Gastroenterology. 2019;157(1):65–73. e5.

    Article  CAS  PubMed  Google Scholar 

  50. Nistel M, et al. Ciclesonide Impacts Clinicopathological features of Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2021;9(11):4069–74.

    Article  CAS  PubMed  Google Scholar 

  51. Jensen ET, et al. Longitudinal growth outcomes following first-line treatment for Pediatric patients with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2019;68(1):50–5.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Golekoh MC, et al. Adrenal insufficiency after chronic swallowed glucocorticoid therapy for eosinophilic esophagitis. J Pediatr. 2016;170:240–5.

    Article  CAS  PubMed  Google Scholar 

  53. Hsu S, et al. Adrenal insufficiency in Pediatric Eosinophilic Esophagitis Patients treated with swallowed topical steroids. Pediatr Allergy Immunol Pulmonol. 2017;30(3):135–40.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Bose P, et al. Adrenal insufficiency in children with eosinophilic esophagitis treated with topical corticosteroids. J Pediatr Gastroenterol Nutr. 2020;70(3):324–9.

    Article  PubMed  Google Scholar 

  55. Ahmet A, et al. Adrenal suppression in children treated with swallowed fluticasone and oral viscous budesonide for eosinophilic esophagitis. Allergy Asthma Clin Immunol. 2016;12:49.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Philpott H, et al. Systematic review: adrenal insufficiency secondary to swallowed topical corticosteroids in eosinophilic oesophagitis. Aliment Pharmacol Ther. 2018;47(8):1071–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Franciosi JP, et al. Proton Pump inhibitor therapy for eosinophilic esophagitis: history, mechanisms, efficacy, and future directions. J Asthma Allergy. 2022;15:281–302.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Liacouras CA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128(1):3–20. e6; quiz 21 – 2.

    Article  PubMed  Google Scholar 

  59. Dellon ES et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol, 2013. 108(5): p. 679 – 92; quiz 693.

  60. Molina-Infante J, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut. 2016;65(3):524–31.

    Article  CAS  PubMed  Google Scholar 

  61. Navarro P, et al. Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis. Dig Liver Dis. 2021;53(11):1479–85.

    Article  CAS  PubMed  Google Scholar 

  62. Thakkar KP, et al. Effect of Proton pump inhibitor treatment in PPI non-responsive patients with eosinophilic esophagitis. J Gastrointestin Liver Dis. 2023;32(1):15–22.

    Article  PubMed  Google Scholar 

  63. Lucendo AJ, Arias A, Molina-Infante J. Efficacy of Proton Pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and Meta-analysis. Clin Gastroenterol Hepatol. 2016;14(1):13–22e1.

    Article  CAS  PubMed  Google Scholar 

  64. Thakkar KP, et al. Long-term efficacy of proton pump inhibitors as a treatment modality for eosinophilic esophagitis. Dig Liver Dis. 2022;54(9):1179–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Gutierrez-Junquera C, et al. Proton Pump inhibitor therapy in Pediatric Eosinophilic Esophagitis: predictive factors and long-term step-down efficacy. J Pediatr Gastroenterol Nutr. 2023;76(2):191–8.

    Article  CAS  PubMed  Google Scholar 

  66. Turshudzhyan A, et al. Rebuilding trust in proton pump inhibitor therapy. World J Gastroenterol. 2022;28(24):2667–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Hirano I, et al. Efficacy of Dupilumab in a phase 2 Randomized Trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111–122e10.

    Article  CAS  PubMed  Google Scholar 

  68. Dellon ES, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387(25):2317–30. Results of the pivotal trials of dupilumab which is the first, and only, FDA approved medication to treat adolescent and adult eosinophilic esophagitis. It also represents the first time a biologic has been employed to treat eosinophilic esophagitis, laying the foundation for future biologic trials.

    Article  CAS  PubMed  Google Scholar 

  69. Dellon ES, et al. Long-term efficacy and tolerability of RPC4046 in an open-label extension trial of patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2021;19(3):473–483e17.

    Article  CAS  PubMed  Google Scholar 

  70. Chretien B, et al. Dupilumab-associated arthralgia: an observational retrospective study in VigiBase((R)). Br J Dermatol. 2021;185(2):464–5.

    Article  CAS  PubMed  Google Scholar 

  71. Bachert C, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–50.

    Article  CAS  PubMed  Google Scholar 

  72. Spergel BL, et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. Ann Allergy Asthma Immunol. 2022;128(5):589–93.

    Article  CAS  PubMed  Google Scholar 

  73. Aceves SS, et al. Clinical guidance for the use of dupilumab in eosinophilic esophagitis: a yardstick. Ann Allergy Asthma Immunol. 2023;130(3):371–8.

    Article  CAS  PubMed  Google Scholar 

  74. Schoepfer AM, et al. Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol. 2010;105(5):1062–70.

    Article  PubMed  Google Scholar 

  75. Moawad FJ, et al. Systematic review with meta-analysis: endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;46(2):96–105.

    Article  CAS  PubMed  Google Scholar 

  76. Moole H, et al. Role of endoscopic esophageal dilation in managing eosinophilic esophagitis: a systematic review and meta-analysis. Med (Baltim). 2017;96(14):e5877.

    Article  Google Scholar 

  77. Reed CC, et al. Combined and alternating topical steroids and Food Elimination Diet for the treatment of Eosinophilic Esophagitis. Dig Dis Sci. 2018;63(9):2381–8.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Reed CC, et al. Combination Therapy with Elimination Diet and Corticosteroids is effective for adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2019;17(13):2800–2.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Heine RG, Cameron PR, Alex DJ, Oliver G, Hardikar MR, Chow W, McWilliam CW, Moore VL, Kakakios DJ, Cheah AM, O’Loughlin E, Axelrad E, Allen C. Effect of a 4-food elimination diet and omeprazole in children with eosinophilic esophagitis – a randomized, controlled trial. J Allergy Clin Immunol. 2019;143(2):AB309.

    Article  Google Scholar 

  80. Koutlas NT, Dellon ES. Progression from an inflammatory to a fibrostenotic phenotype in Eosinophilic Esophagitis. Case Rep Gastroenterol. 2017;11(2):382–8.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Dellon ES, et al. A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc. 2014;79(4):577–85e4. ● This retrospective, cross-sectional study of children and adults who have eosinophilic esophagitis found that the risk of developing a fibrostenotic disease phenotype doubled with every 10 years of life. These findings contribute to the recognition of eosinophilic esophagitis as progressive disease that necessitates treatment depsite the presence of current symptoms.

    Article  PubMed  Google Scholar 

  82. Schoepfer AM, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145(6):1230–6e1.

    Article  PubMed  Google Scholar 

  83. Lipka S, Kumar A, Richter JE. Impact of Diagnostic Delay and other Risk factors on eosinophilic Esophagitis phenotype and esophageal diameter. J Clin Gastroenterol. 2016;50(2):134–40.

    Article  CAS  PubMed  Google Scholar 

  84. Dellon ES, et al. Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. Mod Pathol. 2015;28(3):383–90.

    Article  PubMed  Google Scholar 

  85. Shah A, et al. Histopathologic variability in children with eosinophilic esophagitis. Am J Gastroenterol. 2009;104(3):716–21.

    PubMed  Google Scholar 

  86. Arnim UV, et al. Monitoring patients with eosinophilic Esophagitis in Routine Clinical Practice - International Expert Recommendations. Clin Gastroenterol Hepatol; 2022.

  87. Godwin B, Wilkins B, Muir AB. EoE disease monitoring: where we are and where we are going. Ann Allergy Asthma Immunol. 2020;124(3):240–7.

    Article  PubMed  Google Scholar 

  88. Hoffmann NV, Keeley K, Wechsler JB. Esophageal distensibility defines fibrostenotic severity in Pediatric Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2023;21(5):1188–97. e4.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

No funding was received to assist with the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA

    Colby S. Sharlin, Vincent A. Mukkada, Philip E. Putnam & Scott M. Bolton

  2. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    Vincent A. Mukkada, Philip E. Putnam & Scott M. Bolton

  3. Cincinnati Children’s Hospital, 3333 Burnet Ave, Cincinnati, OH, 45229, USA

    Scott M. Bolton

Authors
  1. Colby S. Sharlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vincent A. Mukkada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip E. Putnam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Scott M. Bolton
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

C.S. and S.B.wrote the main manuscript text. All authors reviewed and edited the manuscript.

Corresponding author

Correspondence to Scott M. Bolton.

Ethics declarations

Human and Animal Rights

This article does not contain any studies of human or animal subjects performed by any of the authors.

Competing Interests

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharlin, C.S., Mukkada, V.A., Putnam, P.E. et al. Treatment of Pediatric Eosinophilic Esophagitis: Traditional and Novel Therapies. Curr Gastroenterol Rep 25, 289–298 (2023). https://doi.org/10.1007/s11894-023-00893-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-023-00893-6

Keywords

Search

Navigation